Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Identification of novel inhibitors to prevent microbial production of pro-diabetic metabolites

Objetivo

The gut microbiota has been associated with metabolic diseases, such as type 2 diabetes. In my ERC consolidator award we demonstrated that the gut microbiota is altered following bariatric surgery and that the altered microbiota may be directly linked to some of the metabolic improvements observed following surgery. Interestingly, improved metabolism was associated with altered metabolite production capacity from the microbiota and we observed that a metabolite, imidazole propionate, was reduced after surgery. In associated projects we have demonstrated that imidazole propionate is associated with type 2 diabetes in humans and induce insulin resistance in primary hepatocytes and when injected into mice. Imidazole propionate is synthesized by the microbial enzyme UrdA from histidine. This POC will explore the potential of identifying inhibitors of UrdA to reduce production of imidazole propionate and thereby improve insulin sensitivity. If successful we envision a new class of diabetes medication based on the concept of drug the bug.

Régimen de financiación

ERC-POC - Proof of Concept Grant

Institución de acogida

GOETEBORGS UNIVERSITET
Aportación neta de la UEn
€ 149 700,75
Dirección
VASAPARKEN
405 30 Goeteborg
Suecia

Ver en el mapa

Región
Södra Sverige Västsverige Västra Götalands län
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 149 700,75

Beneficiarios (1)